Reshma Kewalramani, Vertex CEO
July 11, 2022 10:55 AM EDTUpdated 11:16 AM
Deals
Cell/Gene Tx

Ver­tex nabs Vi­a­Cyte's ri­val di­a­betes stem cell treat­ment, ac­quir­ing the biotech for $320M in cash

Max Gelman

Senior Editor

Less than a week af­ter the FDA lift­ed a hold on Ver­tex’s stem cell ther­a­py for type 1 di­a­betes, the Boston com­pa­ny is buy­ing out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times